Blueprint Medicines signs deals for up to $1.25B in cash, earnouts


Blueprint Medicines Corp. has struck deals with Sixth Street and Royalty Pharma plc to bring in up to $1.25 billion.

Previous DOJ sues to block Booz Allen's acquisition of EverWatch
Next Outgoing Amazon SVP tapped to lead San Francisco health startup